BeOne's Drug Receives FDA Accelerated Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ONC?
Source: stocktwits
- FDA Accelerated Approval: BeOne's BEQALZI receives FDA accelerated approval, marking the first new B-cell lymphoma 2 inhibitor approved in nearly a decade, which signifies a major advancement in treating relapsed or refractory mantle cell lymphoma and is expected to enhance the company's market competitiveness.
- Clinical Data Support: The drug demonstrated a 52% overall response rate and a 16% complete response rate in clinical trials, with a median duration of response of 15.8 months, indicating strong performance in terms of efficacy and tolerability, potentially attracting more patients to its use.
- Market Potential: With approximately 3,300 new mantle cell lymphoma patients diagnosed annually in the U.S., the approval of BEQALZI provides a new treatment option for these patients, likely driving BeOne's market share growth in the oncology sector.
- Regulatory Follow-Up: Despite the accelerated approval, BeOne stated that continued approval will depend on the results of confirmatory trials, indicating that the company must continue to invest resources to ensure long-term market compliance for the drug.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONC
Wall Street analysts forecast ONC stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 315.070
Low
385.00
Averages
403.76
High
424.00
Current: 315.070
Low
385.00
Averages
403.76
High
424.00
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Grants Accelerated Approval for BEQALZI as New BCL2 Inhibitor
- FDA Accelerated Approval: BEQALZI (sonrotoclax) has received accelerated approval from the FDA, marking it as the first new BCL2 inhibitor in a decade in the U.S., specifically designed for relapsed or refractory (R/R) mantle cell lymphoma (MCL), representing a significant advancement in treatment options.
- Clinical Data Support: In the Phase 1/2 study, BEQALZI demonstrated a 52% overall response rate (ORR) and a 16% complete response rate (CR), indicating its ability to provide effective disease control in settings with limited treatment choices, fundamentally changing clinical treatment approaches.
- Global Market Potential: BEQALZI is not only approved in the U.S. but also in China for R/R MCL and chronic lymphocytic leukemia (CLL) patients, showcasing its broad application potential in the global market and enhancing BeOne's competitiveness in oncology.
- Future Research Directions: Continued approval of BEQALZI is contingent upon results from the confirmatory CELESTIAL-RRMCL trial, and sonrotoclax is also being studied in combination with other therapies, with updated data expected to be presented at the 2026 ASCO Annual Meeting, further advancing its clinical application.
See More
BeOne's Drug Receives FDA Accelerated Approval
- FDA Accelerated Approval: BeOne's BEQALZI receives FDA accelerated approval, marking the first new B-cell lymphoma 2 inhibitor approved in nearly a decade, which signifies a major advancement in treating relapsed or refractory mantle cell lymphoma and is expected to enhance the company's market competitiveness.
- Clinical Data Support: The drug demonstrated a 52% overall response rate and a 16% complete response rate in clinical trials, with a median duration of response of 15.8 months, indicating strong performance in terms of efficacy and tolerability, potentially attracting more patients to its use.
- Market Potential: With approximately 3,300 new mantle cell lymphoma patients diagnosed annually in the U.S., the approval of BEQALZI provides a new treatment option for these patients, likely driving BeOne's market share growth in the oncology sector.
- Regulatory Follow-Up: Despite the accelerated approval, BeOne stated that continued approval will depend on the results of confirmatory trials, indicating that the company must continue to invest resources to ensure long-term market compliance for the drug.
See More
BeOne Medicines Receives FDA Accelerated Approval for Beqalzi
- FDA Accelerated Approval: BeOne Medicines' lymphoma therapy Beqalzi has received accelerated approval from the FDA, marking the first BCL2 inhibitor approved in the U.S. in a decade, representing a significant breakthrough for the company in cancer treatment.
- Significant Market Potential: As a late-line treatment option, the drug targets approximately 3,300 newly diagnosed adults with relapsed or refractory mantle cell lymphoma each year, expected to significantly enhance treatment options and quality of life for patients.
- Ongoing Research Requirement: The continued approval of Beqalzi is contingent upon positive data from the ongoing CELESTIAL-RRMCL confirmatory trial, which is being conducted internationally to ensure the drug's long-term efficacy and safety.
- Revenue Guidance Increase: BeOne projects 2026 revenue between $6.3 billion and $6.5 billion, raising guidance by $100 million, reflecting strong market demand for the new therapy and the company's confidence in future growth.
See More
BeOne Medicines AG Q1 2026 Earnings Call Highlights
- Guidance Upgrade: BeOne Medicines AG raised its 2026 revenue guidance by $100 million, now projecting revenue between $6.3 billion and $6.5 billion, reflecting strong market performance and confidence in future growth.
- Sales Growth: Product revenue reached $1.5 billion in Q1, representing a 34% year-over-year increase, with BRUKINSA sales at $1.1 billion, up 38%, demonstrating the company's leadership position and sustained demand in the BTK market.
- R&D Advancements: The company acquired an exclusive option to license a novel PD-1 VEGF CTLA-4 trispecific antibody, expected to enter clinical trials in June, marking a strategic expansion in the field of tumor immunotherapy.
- Improved Financial Performance: Q1 gross margin improved to 89%, with operating income of $250 million and net income of $227 million, showcasing effective cost control and enhanced profitability measures.
See More
BeiGene Q1 2026 Earnings Exceed Expectations with Strong Revenue Growth
- Strong Performance: BeiGene reported a Q1 2026 non-GAAP EPS of $3.24 and revenue of $1.51 billion, reflecting a 34.8% year-over-year increase, exceeding market expectations by $70 million, indicating robust market performance and profitability.
- Core Product Growth: Global revenues for foundational drug BRUKINSA (zanubrutinib) reached $1.1 billion, up 38% year-over-year, which not only reflects strong market acceptance but also lays a solid foundation for future revenue growth.
- Guidance Adjustment: The company raised its FY 2026 total revenue guidance to $6.3 to $6.5 billion, slightly above the consensus of $6.38 billion, demonstrating management's confidence in future performance and optimistic market demand.
- Operational Efficiency Maintained: GAAP gross margin remains in the high 80% range, with GAAP operating expenses projected between $4.7 to $4.9 billion, indicating the company's ability to control costs while maintaining strong profitability and operational efficiency.
See More
Latest Wall Street Rating Updates
- Apple Rating Reaffirmed: Bernstein raised Apple's price target from $340 to $350, anticipating a 17% revenue growth in FQ2 and a guidance of 14-17% for FQ3, with gross margins at 49.3%, indicating strong market performance and future growth potential.
- KE Holdings Upgrade: Goldman Sachs upgraded KE Holdings from neutral to buy, believing the recent stock price pullback provides an attractive re-entry point for investors, reflecting confidence in the Chinese real estate market.
- Palantir and AMD Downgrade: HSBC downgraded Palantir from buy to hold due to increasing competition; it also downgraded AMD, citing significant stock price appreciation and limited future earnings upside.
- Packaging Corp Upgraded to Buy: Deutsche Bank upgraded Packaging Corp from hold to buy, raising the price target to $256 based on strong Q1 performance and positive management outlook, indicating a pivotal moment for the company in the packaging industry.
See More
FDA Grants Accelerated Approval for BEQALZI as New BCL2 Inhibitor
- FDA Accelerated Approval: BEQALZI (sonrotoclax) has received accelerated approval from the FDA, marking it as the first new BCL2 inhibitor in a decade in the U.S., specifically designed for relapsed or refractory (R/R) mantle cell lymphoma (MCL), representing a significant advancement in treatment options.
- Clinical Data Support: In the Phase 1/2 study, BEQALZI demonstrated a 52% overall response rate (ORR) and a 16% complete response rate (CR), indicating its ability to provide effective disease control in settings with limited treatment choices, fundamentally changing clinical treatment approaches.
- Global Market Potential: BEQALZI is not only approved in the U.S. but also in China for R/R MCL and chronic lymphocytic leukemia (CLL) patients, showcasing its broad application potential in the global market and enhancing BeOne's competitiveness in oncology.
- Future Research Directions: Continued approval of BEQALZI is contingent upon results from the confirmatory CELESTIAL-RRMCL trial, and sonrotoclax is also being studied in combination with other therapies, with updated data expected to be presented at the 2026 ASCO Annual Meeting, further advancing its clinical application.
See More
BeOne's Drug Receives FDA Accelerated Approval
- FDA Accelerated Approval: BeOne's BEQALZI receives FDA accelerated approval, marking the first new B-cell lymphoma 2 inhibitor approved in nearly a decade, which signifies a major advancement in treating relapsed or refractory mantle cell lymphoma and is expected to enhance the company's market competitiveness.
- Clinical Data Support: The drug demonstrated a 52% overall response rate and a 16% complete response rate in clinical trials, with a median duration of response of 15.8 months, indicating strong performance in terms of efficacy and tolerability, potentially attracting more patients to its use.
- Market Potential: With approximately 3,300 new mantle cell lymphoma patients diagnosed annually in the U.S., the approval of BEQALZI provides a new treatment option for these patients, likely driving BeOne's market share growth in the oncology sector.
- Regulatory Follow-Up: Despite the accelerated approval, BeOne stated that continued approval will depend on the results of confirmatory trials, indicating that the company must continue to invest resources to ensure long-term market compliance for the drug.
See More
BeOne Medicines Receives FDA Accelerated Approval for Beqalzi
- FDA Accelerated Approval: BeOne Medicines' lymphoma therapy Beqalzi has received accelerated approval from the FDA, marking the first BCL2 inhibitor approved in the U.S. in a decade, representing a significant breakthrough for the company in cancer treatment.
- Significant Market Potential: As a late-line treatment option, the drug targets approximately 3,300 newly diagnosed adults with relapsed or refractory mantle cell lymphoma each year, expected to significantly enhance treatment options and quality of life for patients.
- Ongoing Research Requirement: The continued approval of Beqalzi is contingent upon positive data from the ongoing CELESTIAL-RRMCL confirmatory trial, which is being conducted internationally to ensure the drug's long-term efficacy and safety.
- Revenue Guidance Increase: BeOne projects 2026 revenue between $6.3 billion and $6.5 billion, raising guidance by $100 million, reflecting strong market demand for the new therapy and the company's confidence in future growth.
See More
BeOne Medicines AG Q1 2026 Earnings Call Highlights
- Guidance Upgrade: BeOne Medicines AG raised its 2026 revenue guidance by $100 million, now projecting revenue between $6.3 billion and $6.5 billion, reflecting strong market performance and confidence in future growth.
- Sales Growth: Product revenue reached $1.5 billion in Q1, representing a 34% year-over-year increase, with BRUKINSA sales at $1.1 billion, up 38%, demonstrating the company's leadership position and sustained demand in the BTK market.
- R&D Advancements: The company acquired an exclusive option to license a novel PD-1 VEGF CTLA-4 trispecific antibody, expected to enter clinical trials in June, marking a strategic expansion in the field of tumor immunotherapy.
- Improved Financial Performance: Q1 gross margin improved to 89%, with operating income of $250 million and net income of $227 million, showcasing effective cost control and enhanced profitability measures.
See More
BeiGene Q1 2026 Earnings Exceed Expectations with Strong Revenue Growth
- Strong Performance: BeiGene reported a Q1 2026 non-GAAP EPS of $3.24 and revenue of $1.51 billion, reflecting a 34.8% year-over-year increase, exceeding market expectations by $70 million, indicating robust market performance and profitability.
- Core Product Growth: Global revenues for foundational drug BRUKINSA (zanubrutinib) reached $1.1 billion, up 38% year-over-year, which not only reflects strong market acceptance but also lays a solid foundation for future revenue growth.
- Guidance Adjustment: The company raised its FY 2026 total revenue guidance to $6.3 to $6.5 billion, slightly above the consensus of $6.38 billion, demonstrating management's confidence in future performance and optimistic market demand.
- Operational Efficiency Maintained: GAAP gross margin remains in the high 80% range, with GAAP operating expenses projected between $4.7 to $4.9 billion, indicating the company's ability to control costs while maintaining strong profitability and operational efficiency.
See More
Latest Wall Street Rating Updates
- Apple Rating Reaffirmed: Bernstein raised Apple's price target from $340 to $350, anticipating a 17% revenue growth in FQ2 and a guidance of 14-17% for FQ3, with gross margins at 49.3%, indicating strong market performance and future growth potential.
- KE Holdings Upgrade: Goldman Sachs upgraded KE Holdings from neutral to buy, believing the recent stock price pullback provides an attractive re-entry point for investors, reflecting confidence in the Chinese real estate market.
- Palantir and AMD Downgrade: HSBC downgraded Palantir from buy to hold due to increasing competition; it also downgraded AMD, citing significant stock price appreciation and limited future earnings upside.
- Packaging Corp Upgraded to Buy: Deutsche Bank upgraded Packaging Corp from hold to buy, raising the price target to $256 based on strong Q1 performance and positive management outlook, indicating a pivotal moment for the company in the packaging industry.
See More
